Biofrontera AG
B8FK
Company Profile
Business description
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
Contact
Hemmelrather Weg 201
LeverkusenNW51377
DEUT: +49 214876320
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
69
Stocks News & Analysis
stocks
Apple earnings: A smooth transition despite continued memory and supply headwinds
Shares fell as investors digested the latest earnings.
stocks
Two new ASX names added to our Global Best Stock Ideas
Our full global list includes 78 companies from around the world.
stocks
Big four bank holds up in weakening economic conditions
Major bank earnings hold up in challenging conditions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,954.90 | 54.00 | -0.60% |
| CAC 40 | 8,191.48 | 171.17 | 2.13% |
| DAX 40 | 26,368.80 | 504.18 | 1.95% |
| Dow JONES (US) | 51,786.72 | 197.26 | -0.38% |
| FTSE 100 | 10,839.26 | 200.83 | 1.89% |
| HKSE | 23,919.50 | 393.53 | 1.67% |
| NASDAQ | 25,372.01 | 207.65 | 0.83% |
| Nikkei 225 | 62,188.63 | 893.23 | -1.42% |
| NZX 50 Index | 13,783.45 | 63.19 | 0.46% |
| S&P 500 | 7,568.92 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,834.50 | 52.30 | -0.59% |
| SSE Composite Index | 3,686.17 | 78.07 | 2.16% |